Dalpiciclib

Dalpiciclib
Clinical data
Other names	SHR-6390
Identifiers
	IUPAC name 6-Acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;
CAS Number	1637781-04-4;
PubChem CID	86279927;
IUPHAR/BPS	11189;
DrugBank	DB17456;
ChemSpider	114951729;
UNII	5ZHA5P4PFX;
ChEMBL	ChEMBL4802161;
Chemical and physical data
Formula	C25H30N6O2
Molar mass	446.555 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)C4CCNCC4)C5CCCC5)C(=O)C;
	InChI InChI=1S/C25H30N6O2/c1-15-20-14-28-25(29-21-8-7-18(13-27-21)17-9-11-26-12-10-17)30-23(20)31(19-5-3-4-6-19)24(33)22(15)16(2)32/h7-8,13-14,17,19,26H,3-6,9-12H2,1-2H3,(H,27,28,29,30); Key:SGJLSPUSUBJWHO-UHFFFAOYSA-N;

Dalpiciclib is a drug for the treatment of various forms of cancer.^[1]

In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.^[2]

Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.^[3]

References

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.